Aclarion (NASDAQ:ACON) Rating Increased to Hold at Wall Street Zen

Aclarion (NASDAQ:ACON) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Aclarion Trading Down 8.3%

Shares of ACON opened at $5.39 on Friday. The stock’s 50-day moving average price is $6.68 and its two-hundred day moving average price is $7.24. Aclarion has a 1 year low of $5.02 and a 1 year high of $3,499.51. The stock has a market cap of $3.61 million, a P/E ratio of -0.36 and a beta of 1.43.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.64) by ($0.29). Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%.The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. As a group, equities analysts forecast that Aclarion will post -263.33 EPS for the current year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.